Fernandez et al., gene-based fam-based AD Evaluation of gene-based family-based methods to detect novel genes 1 associated with familial late onset Alzheimer disease.
Introduction 45
Alzheimer disease (AD) is a complex condition for which almost 50% of its phenotypic variability is due to 46 genetic causes; yet, only 30% of the genetic variability is explained by known markers (Ridge et al. 2016 ). 47 GWAS studies have identified more than 20 risk loci (Lambert et al. 2013) ; and sequencing studies have 48 identified additional genes harboring low frequency variants with large effect size (TREM2, PDL3, UNC5C, 49 SORL1, ABCA7, (Sims et al. 2017) ). Recent studies also indicate that Late-Onset AD (LOAD) families are 50 enriched for genetic risk factors (Cruchaga et al. 2017) . Therefore studying those families may lead to the 51 identification of novel variants and genes (Cruchaga et al. 2014 ; Guerreiro et al. 2013 ). 52 53 Current consensus is that the missing heritability for complex traits and AD may be hidden under the effect of 54 rare variants with low to moderate effect on disease risk (Frazer et al. 2009 ; Manolio et al. 2009 ; Cirulli and 55 Goldstein 2010). The rarity of these markers requires specific study designs and statistical analysis for their 56 detection. The simplest approach to detect rare variants for association is to test each variant individually using 57 standard contingency table and regression methods. But due to the few observations of the rare minor allele at a 58 specific variant, the statistical power to detect association with any rare variant is limited; hence, extremely 59 large samples are required and a more stringent multiple-test correction applies as compared to common 60 variants (Bansal et al. 2010; B. Li and Leal 2008) . It has been acknowledged that the best alternative is to 61 collapse sets of pre-defined candidate rare variants within significant units, usually genes (gene-based sets) ( for both trait-increasing and trait-decreasing variants; it selects optimal frequency thresholds for burden tests of 73 rare variants and estimates p-values analytically or by permutation (Price et al. 2010 ). Variance-componence 74 methods test for association by evaluating the distribution of genetic effects for a group of variants while 75 appropriately weighting the contribution of each variant. The sequence kernel association test (SKAT) casts the 76 problem in mixed models , and in the absence of covariates, SKAT reduces to C-alpha test. 77 (Neale et al. 2011 ). Finally, collapsing and variance component tests can be combined into one statistical 78 method, the SKAT-O approach , which is statistically efficient regardless of the direction and 79 effect of the variants studied. 80 81 All these methods were initially designed for unrelated case-control study designs; but given the rarity of these 82 variants, large datasets are required to achieve statistical power. (Laird and Lange 2006) . Alternatively, family-83 based studies in which several family members share the same phenotype may provide more statistical power 84 than regular case-controls studies ( nature of Alzheimer disease it is often difficult to obtain genetic information from parents (to conform trios), or 88 nuclear family units. The usual pedigree in familial LOAD corresponds to incomplete, large familial units 89 (Figure 1) . Most of the initial software for gene-based family-based studies were not suitable for complex 90 pedigrees like those observed in Alzheimer studies, but in recent years a plethora of methods have been 91 developed that take into account complex family structure in gene-based calculations. Among the software that 92 take into account large pedigrees we find SKAT (Wu et (Schaid et al. 2013 ) and RareIBD (Sul et al. 2016) . 95 96 In this study, we wanted to evaluate the performance of the eight most common gene-based family-based 97 methods available using a real dataset, over 250 multiplex families affected with Alzheimer disease, under 98 different conditions and models. We simulated multiple scenarios in which a candidate variant perfectly 99 segregates with disease status to rank the different programs and models. We also tested the performance of 00 these tests at evaluating known causal genes for AD in our cohort. Finally, we performed genome-wide analysis 01
to evaluate the power of each of these tests. Altogether, we discuss the pros and cons of each method that can be 02 very informative for other investigators performing similar analyses: complex diseases in complex, incomplete, 03 large families. We want to emphasize that although this work is centered on AD, the information extracted from 04 this work can be equally applied to other complex traits. Finally, based on the results from the methods 05 analyzed, we present some candidate genes for AD. 06 2 Materials and Methods 07
Cohort 08
The LOAD families included in this study originated from two cohorts: Washington University School of 09
Medicine (WUSM) cohort and ADSP cohort. 10 20 for Indels and RPRS≥-8 for SNPs) (Figure S1 ). We used PLINK1.9 (https://www.cog-58
genomics.org/plink2/ibd) to remove variants out of Hardy Weinberg equilibrium (p-value <1×10 -6 ), with a 59 genotype calling rate below 95%, with differential missingness between cases vs controls, WES vs WGS, or 60 among different sequencing platforms (p-value<1×10 -6 ). 61 62
Samples with more than 10% of missing variants (four samples) and whose genotype data indicated a sex 63 discordant from the clinical database (three samples) were removed from dataset. Individual and familial 64 relatedness was confirmed using identity-by-descent (IBD) calculations, an existing GWAS dataset for these 65
individuals, and the pedigree information. Because many of the ADSP families were also recruited from the 66 NIA-LOAD repository there is a certain overlap (48 individuals) between the WUSM and the ADSP familial 67 cohorts; we kept the duplicated pair that had better genotyping rate after QC. Principal Component Analysis 68 (PCA) was calculated to corroborate ancestry and restrict our analysis to only samples from European American 69 origin. Functional impact and population frequencies of variants were annotated with SnpEff (Cingolani et al. 70 2012). For this analysis, only SNVs with a minor allele frequency (MAF) below 1%, as registered in ExAC 71 (Lek et al. 2016 ),were taken into account. 72 73 We excluded families carrying a known pathogenic mutation in any of the Mendelian genes for Alzheimer 74 disease, Frontotemporal Dementia, or Parkinson disease (Fernández et al. 2017 ). We restricted the selection of 75 families to those families with at least one case and one control in the family, and we excluded any participants 76
initially diagnosed as AD but that turned into other after pathological examination. Finally, our dataset 77
consisted of 1235 non-hispanic whites (NHW), 824 cases and 411 controls, from 285 different families (Table  78 1, Table S1 ). 79 80
Study design & analysis. 81
The goal of this study was to test the performance and power of different gene-based family-based methods 82 available to date, using a real dataset consisting of 1,235 non-hispanic white individuals from 285 families 83 densely affected with AD. We set up three different scenarios to test (Figure 2) . First, using the real phenotype 84 and pedigree structure of 25 from the 285 families, we generated a synthetic dataset with multiple variants and 85 families with perfect segregation. Second, we evaluated different variant-combinations for the APOE gene. 86 Third, we performed genome-wide gene-based analysis accounting only for non-synonymous SNPs with a 87 MAF < 1%. For each one of these scenarios we evaluated the performance of the different gene-based methods 88
(collapsing, variance-component, and transmission disequilibrium) from the following family-based packages: 89 SKAT ( therefore, we ran a total of 25 models ( Table 3 ). The details of each one of these scenarios are described next. 94 95 2.3.1 Simulated data 96
We selected 25 representative families from our entire dataset for which there was genotypic data for three to 97 seven members (Table S2 ). We used the existing family structure and phenotype of these families, and a 98 simulated gene called "GENE-A" containing five variants. We generated several scenarios in which different 99 numbers of families presented perfect segregation with disease status for a variant in GENE-A (Table 4 and 00 Table S2 ). First, we considered a scenario in which only the first five families of the dataset were included in 01 the analyses, and each family presented a different perfectly segregating variant of GENE-A (scenario 5 family 02 carriers (FC) and 0 non-carriers (FNC): 5FC×0FNC). Second, we generated additional scenarios in which we 03 kept the same five families carrier of segregating variants in GENE-A, and added five (scenario 5FC×5FNC), 04
ten (scenario 5FC×10FNC), 15 (scenario 5FC×15FNC), and 20 (scenario 5FC×20FNC) families that were not 05 carriers of any variant in GENE-A. Then, we considered four scenarios of 25 families in which each new 06 scenario added families who were carriers of a segregating variant in GENE-A. We started with the scenario 07 5FC×20FNC, then we simulated ten families carriers and 15 families non-carriers (scenario 10FC×15FNC), 15 08 families carries and 10 families non-carriers (scenario 15FC×10FNC), 20 families carriers and five families 09 non-carriers (scenario 20FC×5FNC) and concluded with a scenario in which all 25 families were carriers of 10 one, of the possible five, segregating variant in GENE-A (scenario 25FC×0FNC). We tested each one of these 11 scenarios with all previously mentioned gene-based methods and software to evaluate their power to associate 12 perfect segregating variants with disease. 13 1997). We tested the power of all previously mentioned gene-based methods and software to detect association 21 of APOE gene with disease in our entire dataset (N=1,235) under different conditions. We first tested all 22 polymorphic variants (nonsynonymous with MAF <1%) in the APOE gene, second we tested only those 23 variants considered to have a high or moderate effect on the protein including rs429358 and rs7412, and then 24 we tested high and moderate variants alone, and finally tested rs429358 and rs7412 alone. 25 26
Genome-wide analyses 27
We performed gene-based burden analysis on a genome-wide level in our entire dataset (families n=285; 28 samples N=1,235) to evaluate the power of each of the previously mentioned methods to detect novel genes 29 significantly associated with disease; only single nucleotide variants (SNVs) with a minor allele frequency 30 equal or below 1%, based on the EXAC dataset ( (QQ) plots from gene-based p-values were generated with the R package "ggplot2" (Wickham 2009 ). We also 33 evaluated the correlation between these methods using Pearson correlation (Pc) and Spearman correlation (Sc) 34 tests on the log of the p-value using R v3.4.0 (R Core Team 2017). Pc evaluates the linear relationship between 35 two continuous variables whereas Sc evaluates the monotonic relationship between two continuous or ordinal 36 variables. 37 38
Software tested 39
A companying supporting file (Supplementary material) provides a summary of the code employed to run 40 each of the programs described below. 41
GSKAT 42
GSKAT (Wang et al. 2013 ) is among the first R packages to come out with the goal of extending burden and 43
kernel-based gene set association tests for population data to related samples with binary phenotypes. To handle 44
the correlated or clustered structure in the family data, GSKAT fits a marginal model with generalized 45 estimated equations (GEE). The basic idea of GEE is to replace the covariance matrix in a generalized linear 46 mix model (GLMM) with a working covariance matrix that reflects the cluster dependencies. Accordingly, 47
GSKAT blends the strengths of kernel machine methods and generalized estimating equations (GEE), to test for 48 the association between a phenotype and multiple variants in a SNP set. We ran GSKAT correcting for sex and 49
first two PCs. 50 51
SKAT 52
The sequence kernel association test SKAT ( , also an R package, is based on a kernel machine regression and can be viewed as an 69 extension of the sequence kernel association test (SKAT and famSKAT) for application to family data with 70 dichotomous traits. FSKAT is based on a GLMM framework. Moreover, because it uses all family samples, 71
FSKAT claims to be more powerful than SKAT that uses only unrelated individuals (founders) in the family 72
data. FSKAT constructs a kinship matrix based on pedigree relationships using the R kinship library. We ran 73
FSKAT correcting for sex and first two PCs. 74 75
EPACTS 76
Efficient and Parallelizable Association Container Toolbox (EPACTS) is a stand-alone software that 77 implements several gene-based statistical tests (CMC, VT and SKAT) and adapts them to complex families by 78 using EMMAX (https://genome.sph.umich.edu/wiki/EPACTS). EPACTS generates a kinship matrix based on 79 BN algorithm and also annotates the genotypic input file and offers filtering tools (frequency and predicted 80 effect of variants) for easier user-selection of variants that go into gene-based analysis. Nonetheless, we used 81 the same set of variants as in other tests, and corrected for sex and first two PCs, to run our analysis with 82 EPACTS. parametric linkage analysis and looks for a rare variants whose segregation pattern among affected and 12
unaffected individuals is different from the predicted distributions based on Mendelian inheritance and 13 computes a statistic measuring the difference. 14 3 Results 15
Simulated dataset 16
Results from the simulated dataset indicate that RVGDT, rareIBD and collapsing-based methods (Burden, CMC 17 and CLP), provided more statistical power than the variance-component methods to detect association of 18 perfectly segregating variants with disease status ( Table 4) . 19 20 In an hypothetical scenario of five families in which each one of these families presents perfect segregation with 21 disease status for a different variant within the same gene (5FC×0NFC), transmission-disequilibrium based 22 methods evaluate this association as significant (even after multiple test correction; e.g. RVGDT p-value=0.004; 23 p-value after multiple test correction 0.004×9 = 0.036). RVGDT reaches a ceiling p-value of 1×10 -4 ; at 10 24 families carriers (FC) plus 15 families non-carriers (FNC). RVGDT was unable to produce a p-value smaller 25 than 9×10 -4 , therefore it is not possible to rank or determine the significance of genes with this p-value. 26
Similarly, RareIBD reports the same p-value for all simulated scenarios, which can be an artifact or a flaw of 27 the program. Collapsing-based methods (Burden, CMC and CLP) started with significant p-values for the 28 5FC×0NFC scenario, but as we added FNC in the analysis, the association became less significant. Then, as we 29 increased the number of FC of segregating variants, the association became more significant. Overall, Transmission-disequilibrium tests and collapsing tests were the models that identified these simulated 42
segregating variants as associated with the phenotype; the CMC model provided by FarVAT-BLUP was the one 43 providing most genome-wide significant p-values, even in the 5FCx0FNC scenario. 44 45
Candidate genes -APOE 46
We examined the performance of four gene-sets generated for the APOE gene with the twenty-two family-47
based gene-based methods in our entire familial cohort. Neither the entire set of polymorphic variants (set 48 "gene" in Table 5 ) nor the set including only rare non-synonymous variants (set "HM" in Table 5) confer risk  49 for these families. The association seems to be driven by the common APOE ε 2 and ε 4 variants, since only 50 when these were considered, either alone (set "ε2ε4" in Table 5 ) or in conjunction with the rest of rare non-51 synonymous variants (set "HMε 2ε4" in 
Genome-wide analyses 57
Overall, we examined eight software and over 22 algorithms for genome-wide association analysis in our 58 extended family dataset of 285 families and 1235 non-hispanic white individuals. We only included in the 59 analysis non-synonymous SNPs with a MAF ≤ 1% and we corrected per sex and first two PCs. All 22 60 algorithms were run using the same input dataset. The results for these 22 algorithms are described grouped per 61 category, as detailed in the following sections. First, we compared the correction effect provided by four kinship 62 matrices ( Figure 3A) . Second, we compare the performance of nine variance-component software and 63
algorithms (Figure 3B) . Third is the comparison of eight collapsing software and algorithms. Fourth, we 64 compare two transmission-disequilibrium tests. We conclude the results section by providing a summary of the 65 pros and cons encountered while running these methods. Overall, most of the gene-based methods tested 66 seemed quite deflated. Only PedGene, FarVAT and Rare-IBD seem to provide values closer or above the 67 expected under the null hypothesis. The most efficient in terms of power and p-value inflation appears to be 68
FarVAT with BLUP correction. 69 70
Kinship matrices 71
We tested the correction provided by four kinship matrices using the SKAT method with EMMAX correction 72 implemented in the R package SKATv2. The four kinship matrices tested were pedigree calculation (PED), 73
Identity By State (IBS) estimation, Balding-Nichols (BN) estimation, and the kinship generated by EPACTS 74 (HR) which is also based on BN algorithm (Figure 3A) . the IBS matrix provided to our dataset the best balance between covariance-correction and overcorrection. 87 88
Collapsing tests 89
The collapsing methods tested from four different software (PedGene, FarVAT, EPACTS and GSKAT) were 90
Burden, CMC and VT (Figure 3c) . In order to compare the different tests, we followed a similar approach as 91 above, and we ran the different software with the same imputed file and compared the λ .
92
In our analyses, the burden test by GSKAT presented the most deflated values; although the lambda does not 93 illustrate so (GSKAT-Burden λ =1.71, Table 6 model is the software that provided most significant p-values; however, these are clearly inflated compared to 03 the predicted p-values (Pedgene-Burden λ =2.99, Table 6 ) and its results were not correlated with any other 04 Collapsing test (Pc and Sc values < 0.1). 05 06
Variance component tests 07
This subset included all the Variance component-based methods available, CLP, CALPHA and SKAT, from six 08 different software: PedGene, FarVAT, FSKAT, EPACTS, SKAT and GSKAT (Figure 3c) . GSKAT was the 09 software presenting more deflated values though the lambda does not illustrate this (GSKAT-SKAT λ = 1.681, 10 Table 6 ) because of the initial inflation among the low or non-significant genes. GSKAT was followed by 11 SKAT and EPACTS which showed similar λ and performance-values for each gene (Pc=0.8, Sc=0.8, Figure 4) . 12 The CLP, CALPHA and SKATO methods by FarVAT-BLUP-CALPHA Pc=0.82 Sc=0.82, Figure 4) . On the other hand, and despite the fact that FarVAT-19 CLP and FarVAT-BLUP-CLP have higher correlation (Pc=0.85, Sc=0.77), these two tests point to different top 20 genes (FarVAT-CLP top gene is MAS1L, and FarVAT-BLIP-CLP top gene is NLRP9). PedGene in the SKAT 21 model is the software that provided the most significant p-values, but we can observe how these are inflated 22
(Pedgene-SKAT λ =3.53, Table 6 ) and that its correlation with other variance component tests is low to null (Pc 23
and Sc values < 0.2). 24 25 3
.3.4 Transmission disequilibrium tests 26
We have tested two transmission disequilibrium tests, RVGDT and Rare-IBD, which are designed to account 27 for large extended families of arbitrary structure (Figure 3d ). Of these two, RVGDT is the test that more 28 closely approached the expected under the null (λ=0.99), whereas Rare-IBD provided slightly inflated p-values 29 (λ=1.450, Table 6 ). The correlation between these two methods was very low (Pearson correlation = 0.23, 30 Spearman correlation = 0.17). A common issue with both methods is that we could see some stratification 31 towards more significant p-values which made it difficult to determine a top significant gene. 32 33 3
.3.5 PROS and COSN of the different gene-based methods 34
Among all the methods tested, EPACTS and FarVAT are the most user-friendly, time-efficient and versatile 35 software. EPACTS is an all-in-one package that annotates the input file, generates the kinship matrix and 36 performs gene-based analysis under different conditions (minor allele frequency and predicted functionality of 37 the variant) with only tag specification. In addition, the program can be run on a genome-wide base or at 38 smaller scale given genes or regions specified by the user. FarVAT can generate the kinship matrix by either 39 using the pedigree relationships or using the genetic relationship among individuals. It does not annotate the 40 input file and requires that the user provide their own set of genes and variants per gene to analyze; it allows the 41 user to choose between BLUP (best linear unbiased prediction) or prevalence to estimate and incorporate 42 random effects on the phenotype. FarVAT has initial conditioning that only takes founder-based MAF, i.e. 43 when a genetic variant has its minor alleles only in non-founders (offspring), these numbers will not be counted. 44 This is a big difference with respect to the other programs that take into account all variants regardless of their 45 presence in founders or not. Since for many of our families we only had genetic data for siblings, i.e. we did not 46 have genetic data for founders, we ran FarVAT with the "-freq all" option, so all variants would be included 47 regardless if they are present in founders or not. 48 49 FSKAT, GSKAT and SKAT require of some R knowledge from the user, and are less flexible. For FSKAT and 50
GSKAT the user has to provide a genotype, a phenotype, and a gene-set file. For SKAT the user has to 51 additionally provide the kinship matrix. Because these programs were designed to run on a per gene basis, these 52 take longer to compute and to be run on a genome-wide level than EPACTS or FarVAT, even if the user 53 parallelizes computation. PedGene is also an R package that requires a genotype, a phenotype file with 54 complete pedigree information (to generate the kinship matrix), and a gene-set file. PedGene provides 55 phenotype adjustment by logistic regression on the trait of interest, but it does not allow for extra covariates, 56 which prohibits correction by multiple PCs or other variables. RVGDT is a python based program, quite user-57 friendly since it is operated with simple command-line but is limited in its options. Similar to FSKAT, GSKAT 58 and SKAT, it is designed to be run on a per-gene basis for which loops and parallelization have to be set up for 59 genome-wide testing. The same goes for RareIBD which requires a genotype, a phenotype, and a Kinship 60 coefficient file for each gene that the user wants to test. For each gene the program computes first statistics for 61 each founder within each family and then calculates the gene-based p-value. The first step of this process can 62 easily take between three to five minutes for families with less than 100 individuals; hence, the overall time for 63 one gene is directly dependent on the number of families to test and the time required for a genome-wide 64
analysis is proportional to the number of genes being tested. Although it is possible to parallelize the jobs using 65 a high-performance cluster (if available) this program is the slowest of all tested. 66 67
One of the major drawbacks we found is that some of these programs do not accept missing data (FSKAT or 68
RareIBD) or will not generate a p-value if the gene set contains only one variant (GSKAT, PedGene or 69
FarVAT). FSKAT does not accept missing data, and although it calculates p-values for genes that only have one 70
informative SNP (2154 one-SNP-gene), there were at least 75 (3.26%) of these one SNP-genes for which the 71 returned p-value was "2". GSKAT did not provide p-values for more than 1,875 one-SNP-genes. Pedgene also 72 had trouble generating p-values for 44 one-SNP-genes out of a total of 1,916 singletons. FarVAT did not 73 generate a p-value for the 1,875 one-SNP-genes using the Burden and SKATO models but it generated p-values 74
using the CMC and CLP models for the same 1,875 one-SNP-genes. 75
Candidate genes for FASe project 76
Our results indicate that transmission disequilibrium tests identify genes that have a Mendelian behavior, 77 whereas collapsing and variance-component tests identify genes that confer risk for disease. Therefore, we 78
decided to combine and compare results from all approaches to identify the genes with most consistent results 79 ( Table 7) . 80 81 PEDGENE provided the most significant p-values for NTN5 (Pedgene-Burden p-value = 5.80×10 -8 ; Pedgene-82 SKAT p-value = 1.26×10 -8 ) and ANKRD42 (Pedgene-Burden p-value = 3.62×10 -7 ; Pedgene-SKAT p-value = 83
1.16×10 -7 ). However, the inflated p-values observed and low correlation with any of the other software tested 84
using the same algorithms makes us suspicious of the validity of these results. 85 86 CHRD was the gene with the third most significant p-value. CHRD had a p-value ≤ 5×10 -7 in three different 87 models (FarVAT-CALPHA, FarVAT-SKATO, FarVAT-BLUP-CALPHA). In addition, as we lowered the 88 considered p-value threshold we found that more tests identified CHRD as a potential candidate gene associated 89 with AD. When we lowered the threshold to suggestive genome-wide p-value (p-value≤5×10 -4 ) we found that 90 seven different models identified CHRD as a gene significantly associated with AD. Following the same 91 method we found that CLCN2, MAS1L and PTK2B had p-values ≤ 5×10 -05 in at least three tests, and if we 92 lowered the threshold to ≤ 5×10 -4 p-value, these genes were identified as significant by at least three additional 93 tests. 94 95
Among genes with a p-value ≤ 5×10 -04 ; CPAMD8 was identified by at least nine gene-based methods (FarVAT,  96 FarVAT-BLUP and PedGene). The exact p-value for CPAMD8 could not be estimated by RVGDT as it showed 97 a p-value of 9×10 -04 , which is the most significant p-value provided by this test. Therefore, we cannot conclude 98 that CPAMD8 presented a p-value ≤ 5×10 -04 by RVGDT. CHRD, CLCN2, MAS1L, PTK2B and CPAMD8, 99
NLRP9, and HDLBP were also potential novel candidate genes for familial LOAD as they had p-values ≤ 5×10 -00 04 using at least five or more tests ( Table 7) . 01 02 Since these were identified by multiple gene-based methods, we wanted to determine whether any of these 03 seven candidate genes are involved in known AD pathways. Common variants in PTK2B have been associated 04
with AD risk at genome-wide level (J.-C. Lambert et al. 2013 ). Our results indicate there are additional low-05 frequency and rare non-synonymous variants in PTK2B that are associated with AD risk in late-onset families. 06 We used the GeneMANIA (http://pages.genemania.org/) algorithm on the seven candidate genes (CHRD, 07
MAS1L, PTK2B, CPAMD8, NLRP9, CLCN2 and HDLBP) along with known AD-related genes (APP, PSEN1, 08 PSEN2, APOE, TREM2, PLD3, ADAM10) which represent some of the AD genes and pathways (APP-09 metabolism and immune response). GeneMANIA is a software that looks for relationships among a list of given 10 genes by searching within multiple publicly available biological datasets. These datasets include protein-11
protein, protein-DNA and genetic interactions, pathways, reactions, gene and protein expression data, protein 12 domains and phenotypic screening profiles. We found that our candidate genes have genetic interactions and co-13 localization with known AD genes. CHRD and PTK2B are involved in "regulation of cell adhesion" like 14
ADAM10; PTK2B is involved in "regulation of neurogenesis" like APOE and "perinuclear region of cytoplasm" 15 like APP, PSEN1 and PSEN2. Finally, CLCN2 and PTK2B are connected through "regulation of ion transport" 16 ( Figure 5 ). 17 18
The remaining missing heritability in AD, and in many complex diseases, may be found in very rare-variants 20
for which discovery will require either large datasets (eg. the ADSP Discovery Phase which has over 10,000 21 sequenced individuals) or datasets enriched for rare variants (such as families with history of AD). In this study, 22 we present the most comprehensive performance analyses for multiple gene-based methods in 285 families with 23 AD. Some of the current methods available are underpowered or too restrictive to detect genes significantly 24 associated with this disease (Figure 4) . Results from our simulated data (Table 4) show that only certain highly 25 restricted scenarios provide gene-wide significant p-values in a family-based analysis; whereas, similar 26 scenarios in a case-control study would result in gene-wide p-values. To circumvent this power issue, we relied 27 on the combination of multiple evidence towards the same gene. 28 29
One key aspect to adapt gene-based analyses to a family-based context is to account for the population 30 stratification and hidden relatedness that may appear due to the inherent nature of the dataset. To take into 31 account this issue, gene-based algorithms must incorporate kinship matrices to model the relationships among 32
samples. Therefore, an appropriate estimate of the kinship matrix is of utmost importance. In this work we show 33 how different relationship matrices influence results. We tested the three most common types of kinship matrix, 34 pedigree reconstruction (PED), identity by state (IBS), and Balding-Nichols (BN). We show that for a situation 35 of complex incomplete families, correction using PED or BN matrices will lead to an overcorrection of the 36 relationships decreasing the power of these tests (Table 6, Figure 4A) . 37 38 In order to choose the best gene-based algorithm for analysis, it is important to take into account the nature 39
(impact and directionality) of the variants that are being included in the test. Collapsing tests are powerful when 40 a large proportion of variants are causal and effects are in the same direction. Variance-component tests are 41
supposed to be more powerful than collapsing tests because these allow for admixture of risk and protective 42
variants within the region being tested ( approach to perform genome-wide rare variant discovery is to combine different algorithms and look for 47 common signatures across the tests performed. Nonetheless, we are aware that running all available tests is a 48 time-consuming task that requires additional expertise and resources. In our analyses FarVAT, with the BLUP 49 adjustment, provide the best results in terms of significant p-values and inflation, for genome-wide gene-based 50 analysis; it is a fast software that provides results from multiple tests at the same time. The R version of SKAT 51 or EPACTS, would be alternative valid choices, taking into account that these overcorrect and the p-value 52 threshold should be lowered. 53 54 In this study, we identified CHRD as a candidate gene with a genome-wide significant p-value (5×10 -07 ) 55
reported by three tests, and another six genes that had a suggestive genome-wide p-value < 5×10 -04 in at least 56 five and up to nine of the different test performed: CLCN2, CPAMD8, HDLBP, MAS1L, NLRP9 and PTK2B. In 57 addition, these genes seem to have direct and indirect interactions (genetic interaction, co-localization or shared 58 function) with known AD genes (APP, PSEN1, PSEN2, APOE, TREM2, PLD3 and ADAM10). could be due to their close location, both belong to a gene cluster at 3q27. Interestingly, CLCN2 shows co-67 expression with TREM2, which other than being a risk gene for AD, is known to cause leukoencephalopathy in 68 the PLOSL (polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy) form, also known 69
as Nasu-Hakola disease. 70 71 PTK2B, was described as a GWAs hit locus in the largest GWAs meta-analysis conducted to date (Lambert et 72 al. 2013) , and later corroborated by others (Wang et al. 2015; Beecham et al. 2014 ). The protein encoded by 73
PTK2B is a member of the focal adhesion kinase (FAK) family that can be activated by changes in intracellular 74 calcium levels, which are disrupted in AD brains. Its activation regulates neuronal activity such as mitogen-75 activated protein kinase (MAPK) signaling (Rosenthal and Kamboh 2014) . PTK2B could also be involved in 76 hippocampal synaptic function (Lambert et al. 2013) . Although there is no co-expression or genetic interaction 77 between CLCN2 and PTK2B, both are involved in regulation of ion transport. Additionally, PTK2B is involved 78
in regulation of lipidic metabolic processes, like APOE, a cholesterol-related gene. Despite no association has 79 yet been reported between APOE and HDLBP, the High-Density Lipoprotein Binding Protein plays a role in 80 cell sterol metabolism, protecting cells from over-accumulation of cholesterol, which has been reported as risk 81
factor for atherosclerotic vascular diseases. 82 83
CPAMD8 causes a Unique Form of Autosomal-Recessive Anterior Segment Dysgenesis (Cheong et al. 2016). 84 No shared pathway association was found between CPAMD8 and the known AD genes, but it seems to have a 85 genetic interaction with APP (Lin et al. 2010 ). In our study CPAMD8 was identified as a candidate gene (with 86 p-value < 1×10 -4 ) for AD by at least nine gene-based methods from different software, and we found that 87 several variants within this gene show varying degrees of perfect segregation in more than twenty families. 88
Variant p.(Ser1103Ala) segregates with disease status in two families with two and three carriers respectively, 89 and is present in another two families. Variant p.(His465Arg) segregates with disease status in five families 90 with two or three carriers per family and is present in another 11 families. Variant p.(Arg1380Cys) is private to 91 a family with three carriers, p.(Ala1492Pro) is private to a family with five carriers, and p.(Val521Met) is 92 private to a family with three carriers. 93 94 We have reviewed over 22 algorithms from eight different software available for the gene-based analysis in 95 complex families. After a thorough examination of these tests performance under different scenarios, we present 96 a methodology to identify genes associated with the studied phenotype. We have applied this methodology to 97 285 European-American families affected with late onset Alzheimer disease (LOAD). We have identified six 98 candidate genes with suggestive or significant genome-wide p-values and we are confident that some of these 99
genes are truly involved on AD pathology. We thank the Genome Technology Access Center in the Department of Genetics Table 4 . Representation of the segregation pattern of the simulated gene. One (1) means that all cases within the family are carriers of the variant. Zero (0) means that the variant is not present in that family. Table 4 . Gene-based p-values for the simulated dataset under different scenarios for the gene-based methods tested in the subset of 25 families.
GENE-
SET GSKA T 1 Simulated scenarios: 5FC: five families carrier of variants within the hypothetical gene; 5FCx5FNC: five families carrier of variants within the hypothetical gene and five families non-carrier of variants within the hypothetical gene; 5FCx10FNC: five families carrier of variants within the hypothetical gene and ten families non-carrier of variants within the hypothetical gene; 5FCx15FNC: five families carrier of variants within the hypothetical gene and fifteen families non-carrier of variants within the hypothetical gene; 5FCx20FNC: five families carrier of variants within the hypothetical gene and twenty families non-carrier of variants within the hypothetical gene; 10FCx15FNC: ten families carrier of variants within the hypothetical gene and fifteen families non-carrier of variants within the hypothetical gene; 15FCx10FNC: fifteen families carrier of variants within the hypothetical gene and ten families non-carrier of variants within the hypothetical gene; 20FCx5FNC: twenty families carrier of variants within the hypothetical gene and five families non-carrier of variants within the hypothetical gene; 25FC: twenty-five families carrier of variants within the hypothetical gene. *we tested SKAT, CMC and VT on EPACTS, but CMC and VT reported all NA values so data is not shown. . Gene network for the seven candidate genes (CHRD, CLCN2, CPAMD8, HDLBP, MAS1L, NLRP9 and PTK2B) with multiple evidence of a p-value ≤ 5×10 -04 , anchored with known AD genes (APP, PSEN1, PSEN2, APOE, TREM2, ADAM10, PLD3), as described by GeneMania.
